common.study.topics.clinical

Sirolimus Use in Angioplasty for Vascular Access Extension

common.study.values.description

Sirolimus Use in Angioplasty for Vascular Access Extension

Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Sirolimus

3 mg po od loading dose for two days, then 2 mg po od for thirty days

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy

common.study.values.clinical-trial-id

NCT01595841

participant.views.study.view.id

mbk8xd